Loading clinical trials...

Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

Mechanism of Action and Efficacy of Muraglitazar (BMS298585) in the Treatment of Type 2 Diabetic Patients

NCT00094991•Bristol-Myers Squibb

Summary

The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Type 2 diabetes;
•Serum triglyceride concentration \< or = 600 mg/dL;
•Body mass index \< or = 37 kg/m2

Exclusion Criteria

•Type 1 diabetes;
•History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months;
•Congestive heart failure (NYHA Class III and IV);
•Uncontrolled hypertension;
•Women of Child Bearing Potential
•History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease

Locations (2)

Local Institution

San Antonio, Texas, United States

Local Institution

Pisa, Italy

Key Dates

Start Date

May 1, 2004

Primary Completion Date

May 1, 2006

Completion Date

May 1, 2006

Last Updated

September 14, 2010

Enrollment

Estimated participants

Conditions

Diabetes Mellitus, Type 2

Interventions

Muraglitazar

DRUG

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

NCT06959901

Obesity and Diabetes Mellitus, Type 2Diabetes Prevention

View study

RECRUITINGNA

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035

Diabetes Mellitus, Type 2Depressive Symptoms+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 14, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

Inclusion Criteria

Exclusion Criteria

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes

Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use

Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)